1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,022 | 0,025 | 19:05 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 29.06. | Genflow Biosciences PLC Announces Result of AGM | 212 | ACCESS Newswire | LONDON, UK / ACCESS Newswire / June 29, 2026 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company") an emerging leader in the field of longevity research, is pleased to announce... ► Artikel lesen | |
| 29.06. | Genflow Biosciences - Result of AGM | 1 | RNS | ||
| 22.06. | Genflow Biosciences PLC Announces Participation at BIO International Convention 2026 | 205 | ACCESS Newswire | LONDON, UK / ACCESS Newswire / June 22, 2026 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company") an emerging leader in the field of longevity research, today announces Gad... ► Artikel lesen | |
| 22.06. | Genflow Biosciences - Participation at BIO International Convention 2026 | - | RNS | ||
| GENFLOW BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 17.06. | Genflow präsentiert im Oktober Daten zur Gentherapie bei alternden Hunden | 2 | Investing.com Deutsch | ||
| 17.06. | Genflow to present aged dog gene therapy data in October | 4 | Investing.com | ||
| 17.06. | Genflow Biosciences PLC - Company to present at Animal Longevity Summit 2026 | 206 | ACCESS Newswire | THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK... ► Artikel lesen | |
| 17.06. | Genflow Biosciences - Company to present at Animal Longevity Summit 2026 | 2 | RNS | ||
| 04.06. | Genflow Biosciences PLC Announces Notice of AGM | 432 | ACCESS Newswire | Notice of Annual General Meeting and Board Changes LONDON, UK / ACCESS Newswire / June 4, 2026 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company") an emerging leader in the... ► Artikel lesen | |
| 04.06. | Genflow Biosciences - Notice of AGM | 1 | RNS | ||
| 08.05. | Genflow Biosciences PLC Announces Exercise of Warrants and Issue of Equity | 369 | ACCESS Newswire | THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018... ► Artikel lesen | |
| 08.05. | Genflow Biosciences - Exercise of Warrants and Issue of Equity | 2 | RNS | ||
| 30.04. | Genflow Biosciences PLC Announces Final Results | 200 | ACCESS Newswire | THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK... ► Artikel lesen | |
| 30.04. | Genflow Biosciences - Final Results | 4 | RNS | ||
| 28.04. | Genflow Biosciences PLC Announces Expansion of Confidentiality Agreements | 214 | ACCESS Newswire | THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK... ► Artikel lesen | |
| 28.04. | Genflow Biosciences - Expansion of Confidentiality Agreements | 1 | RNS | ||
| 20.04. | Genflow kooperiert mit Acuitas bei Technologie zur Verabreichung von Gentherapien | 1 | Investing.com Deutsch | ||
| 20.04. | Genflow partners with Acuitas for gene therapy delivery tech | 4 | Investing.com | ||
| 20.04. | Genflow Biosciences PLC Announces Strategic Technology Collaboration | 296 | ACCESS Newswire | Genflow Biosciences Enters Strategic Technology Collaboration with Acuitas Therapeutics - Fully Funded, Non-Dilutive Access to World-Class LNP Delivery Platform LONDON, UK / ACCESS Newswire / April... ► Artikel lesen | |
| 20.04. | Genflow Biosciences - Strategic Technology Collaboration | - | RNS |
1 2 3 4 Weiter >>
65 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CRISPR THERAPEUTICS | 51,69 | -2,91 % | H.C. Wainwright reiterates CRISPR Therapeutics stock rating on label expansion | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,320 | -3,76 % | Druck auf Pacific Biosciences nimmt zu: Warum die Geduld der Anleger auf eine harte Probe gestellt wird | Pacific Biosciences gerät zunehmend unter Druck: Die Aktie steht nach einer "significant downward revision of revenue guidance" und dem erzwungenen Aktienrückzug eines Großaktionärs im Fokus. Für Investoren... ► Artikel lesen | |
| DENALI THERAPEUTICS | 23,130 | +0,39 % | Denali Therapeutics Inc.: Denali Therapeutics Enters Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $195 Million | Proceeds from transaction to support advancement of Denali's broad TransportVehicle-enabled clinical portfolio for lysosomal storage disorders and neurodegenerative diseasesDenali was awarded Priority... ► Artikel lesen | |
| VOYAGER THERAPEUTICS | 3,250 | -1,46 % | Voyager Therapeutics, Inc.: Voyager Receives FDA IND Clearance for VY1706, First Gene Therapy Approach to Reducing Tau Production in the Brain for Alzheimer's Disease | - Dosing of adults with early Alzheimer's disease in clinical trial expected H2 2026 - - Comprehensive preclinical program showed compelling pharmacology and safety profile for VY1706 - - VY1706 uses... ► Artikel lesen | |
| BIOAGE LABS | 21,480 | +0,56 % | BioAge Labs: NBC-Komplettexit nach fast +500% Rendite | Was für eine Erfolgsstory: Nachdem die BioAge-Labs-Aktie im Januar bereits eine Performance von bis zu +449% auf den ursprünglichen Empfehlungskurs erreicht hatte, ist der No Brainer Club nun auch mit... ► Artikel lesen | |
| LINEAGE CELL THERAPEUTICS | 1,168 | +1,39 % | Transcript: Lineage Cell Therapeutics Q1 2026 Earnings Conference Call | ||
| BIOPHYTIS | 0,013 | -100,00 % | Biophytis SA - 6-K, Report of foreign issuer | ||
| SERINA THERAPEUTICS | 1,830 | +13,66 % | Serina Therapeutics, Inc.: Serina Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates | Phase 1b Registrational Clinical Study of SER-252 Underway in Advanced Parkinson's Disease; TFL data from the SAD study arm targeted for first half of 2027 - - Closed $21.2 million private placement... ► Artikel lesen | |
| LONGEVERON | 0,643 | +2,08 % | Longeveron Appoints Marie Washburn as Chief Financial Officer | Ms. Washburn has over 20 years of experience in leadership roles in the pharmaceutical and biotech sectorsCorporate focus on delivering top-line results from the Phase 2b clinical trial evaluating... ► Artikel lesen | |
| QIAGEN | 33,150 | -2,84 % | Dividendenbekanntmachungen (07.07.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ABC ARBITRAGE SA FR0004040608 - 0,04 EUR ACCIONA SA ES0125220311 - 5,7486 EUR AMICA SA PLAMICA00010 2,5 PLN 0,5829 EUR ANY BIZTONSAGI... ► Artikel lesen | |
| VERA THERAPEUTICS | 41,740 | -2,84 % | Vera Therapeutics Receives FDA Accelerated Approval for TRUTAKNA for Adult Patients with Primary IgA Nephropathy | TRUTAKNA is the first and only available therapy that binds both B-cell activating factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), addressing the immunological drivers at the source of... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 133,47 | -0,05 % | AbbVie setzt mit Apogee-Übernahme neuen Akzent im Wettlauf um Blockbuster-Biologika | AbbVie stärkt mit der geplanten Übernahme von Apogee Therapeutics seine Position im Markt für Immunologie-Biologika und vertieft damit eine ohnehin schon dominante Wettbewerbsstellung. Der Deal zielt... ► Artikel lesen | |
| BEAM THERAPEUTICS | 36,760 | -3,06 % | Prime Medicine gains after winning arbitration with Beam Therapeutics | ||
| PRAXIS PRECISION MEDICINES | 327,41 | +1,03 % | Praxis Precision Medicines, Inc. - 8-K, Current Report | ||
| COGENT BIOSCIENCES | 39,010 | -2,50 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) | Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria with a well-tolerated... ► Artikel lesen |
GENFLOW BIOSCIENCES PLC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,022 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GENFLOW BIOSCIENCES PLC finden Sie auf Wallstreet Online.